Reports this week that Pfizer intends to shelve the development of its oral PCSK9 inhibitor suggest the future of this therapy may remain in injectables. In its Q2 earnings report earlier this week Pfizer President Mikael Dolston said: “We don’t think that the oral PCSK9 profile would be competitive with the strong LDL lowering seen with ...
Future of PCSK9 inhibitors likely to remain in injectables
By Nicola Garrett
5 Aug 2016